The Catalyst

Most Recent Posts

11.13.13
The report, "Research in Your Backyard:  Pharmaceutical Clinical Trials in Massachusetts," shows widespread clinical research underway throughout the state, including Worcester where we released the report yesterday with the
11.12.13 | By John Castellani

Over the last few weeks we have devoted a fair bit of time and energy on Alzheimer’s disease. Why? It is one of the most complex diseases we face, it currently afflicts more than 5 million people in the U.S. and its current trajectory is worrisome to say the least.

11.08.13

The phrase “strength in numbers” often rings true for the biopharmaceutical industry. This week we were reminded that when it comes to furthering innovation, collaboration is essential to creating a path forward and finding ways to improve patients’ lives.

11.07.13 | By Preet Bilinski

Have you heard of  Batten disease? Or  of Pompe disease? Niemann-Pick Disease? These are just a few of the 7,000 rare diseases that over 30 million Americans live with every day. Another rare disease that you may not be familiar with is Mitochondrial disease. Unfortunately, Art Estopian is too familiar with the disease.

11.05.13

Today, Alzheimer’s affects more than five million people in America. According to the Alzheimer’s Association, that number will triple in the next 40 years, and by 2050, caring for patients with Alzheimer’s and other forms of dementia is expected to cost the United States more than $1 trillion annually. Given the tremendous looming human and financial costs, more and more attention and resources are being devoted to finding new ways to treat those with Alzheimer’s disease and, ultimately, find a cure.

11.05.13 | By John Castellani

Last week, I took part in an interesting multi-stakeholder roundtable convened by NEHI and the California Healthcare Institute (CHI).

11.05.13 | By John Castellani

The U.S. pharmaceutical supply chain is the most secure in the world in part because of strong industry and government collaboration.  One benefit is that American patients can have confidence that the prescription medications they purchase from a reputable pharmacy are true to the label.

11.04.13 | By Raju Kucherlapati, Ph.D.

Personalized Medicine was an emerging field of medicine in 2005 when we first held what was to become an annual event, our personalized medicine conference. The importance of personalized medicine was given a boost by the then U.S. Secretary of Health and Human Services, Michael Leavitt, who said in January 2005, “I believe we are moving into a remarkable and powerful new era in medicine and particularly in prescription drugs.

11.02.13 | By Kaelan Hollon
The old adage that 'you learn something new every day' doesn’t apply to the biopharmaceutical industry; for those researching and developing new medicine, it would be more accurate to say you learn something new every few minutes. Our member companies continue to push the limits of research, and that process keeps our work consistently exciting.  
11.01.13 | By Kristin Van Goor

Less than 15 years ago, submitting an application to the Food and Drug Administration (FDA) for the approval of a new medicine generally involved loading docks, moving trucks, and enough paper to obliterate a small tree farm.  Today, those data once supplied on hundreds of thousands of paper pages are now a structured collection of electronic files submitted to the FDA through a secure portal. 

10.31.13 | By Jay Taylor

Yesterday, the Senate Finance Committee held its first hearing on the Transatlantic Trade and Investment Partnership (TTIP), a comprehensive free trade agreement that the U.S. and European Union have begun negotiating.

10.29.13 | By Mit Spears

Yesterday, I had the opportunity to speak at a conference of regulatory and compliance professionals – those who are dedicated to ensuring that regulation works.

10.29.13

Millions of prescriptions are filled every year in the United States and the patients who depend on these medications must have confidence in their safety and authenticity.

10.29.13 | By John Castellani

A survey commissioned earlier this year by PhRMA shows 86 percent of Americans believe developing cures for more forms of cancer should be one of the top national health priorities.

10.28.13

Until this morning, on the rare occasions when I thought of Omaha, Nebraska, I would conjure up images of Warren Buffett, thick juicy steaks, a clean quiet Midwestern city and friendly, laid-back folks, not necessarily in that order.

I learned today that I was not inaccurate, all of the above is true,  but my picture was far from complete.

Pages